Drug Discovery & Research
AbbVie Bets $710 Million on AI-Designed Drugs as Nvidia-Backed Startup Eyes Public Markets
Iambic Therapeutics secures pharma giant partnership and files for IPO in same-day move that tests whether artificial intelligence can deliver on drug discovery promises.
Health AI Central Editorial Team·September 24, 2026
Drug Discovery & Research
The $8.9 Billion Question: Why AI Drug Discovery Still Has Nothing on Pharmacy Shelves
Three years of sliding approval timelines expose a critical gap between artificial intelligence's preclinical promise and the regulatory infrastructure needed to bring AI-discovered medicines to patients.
Health AI Central Editorial Team·August 10, 2026
Drug Discovery & ResearchPro
Why the FDA Is Betting on Biology-Driven AI to Fix Drug Development's $2 Billion Failure Problem
Mechanistic AI that explains *why* drugs work—rather than just predicting outcomes—could finally give regulators the transparency needed to accelerate drug development and reduce catastrophic trial failures.
Health AI Central Editorial Team·June 26, 2026